Dynavax Adjuvanted Clover Bio's COVID-19 Vaccine Booster Shows Durable Protection Against Omicron

Clover Biopharmaceuticals Ltd's follow-up analysis for efficacy in the SPECTRA Phase 2/3 trial of SCB-2019 COVID-19 vaccine provided high and durable protection in individuals five months after the second dose.
The follow-up analysis involved 26,400 individuals.
Against any variant, efficacy was maintained at 100% against severe COVID-19 and 95% against COVID-19 associated hospitalizations at five months after the second dose in the primary vaccination setting.
Additionally, there was no evidence that clinical efficacy declined over five months in individuals with prior infection who were subsequently boosted with SCB-2019.
Clover's COVID-19 vaccine candidate combines Dynavax Technologies Corporation's DVAX CpG 1018 advanced adjuvant and aluminum hydroxide (alum).
A heterologous booster dose of SCB-2019 in individuals previously receiving two doses of AstraZeneca plc AZN COVID-19 vaccine induced approximately 2-fold higher levels of neutralizing antibodies against the omicron variant compared to individuals receiving three doses of AstraZeneca's vaccine.
A homologous booster dose of SCB-2019 in individuals with prior COVID-19 infection induced multi-fold higher levels of neutralizing antibodies against the omicron variant than individuals receiving three doses of AstraZeneca's COVID-19 vaccine.
The submissions are anticipated to complete in mid-2022 for the China NMPA and by Q3 of 2022 for the WHO and EMA.
Price Action: DVAX shares are up 3.10% at $11.31 during the premarket session on the last check Thursday.